HOME >> MEDICINE >> NEWS
Statins could reduce stroke risk by a third

Statins-drugs that lower LDL cholesterol-substantially reduce the incidence of ischaemic stroke among high-risk individuals, conclude authors of a study in this weeks issue of THE LANCET.

Cholesterol lowering with statins is of known benefit for people at increased risk of heart attack. However, current treatment guidelines do not recommend that doctors take account of a person's risk of stroke when deciding whether to use statin therapy. Rory Collins from the Clinical Trial Service Unit, Oxford, UK, and colleagues report detailed results from a five-year study of the effect of simvastatin or placebo among 20,536 people with either a history of stroke or other cerebrovascular disease (3280 people) or at high risk of stroke for other reasons (17,256 people).

Participants were randomly assigned 40 mg simvastatin daily or matching placebo for five years, which yielded an average reduction in LDL cholesterol of 1 mmol/litre. There was a very definite 25% proportional reduction in the incidence of stroke among patients in the simvastatin group (444 strokes; 4.3%) compared with those in the placebo group (585 strokes; 5.7%). This reflected a 30% proportional reduction in the incidence of 'ischaemic' strokes (ie, due to artery blockage in the brain), with no apparent difference in the incidence of 'haemorrhagic' strokes (ie, due to bleeding into the brain). Although the stroke rate was not significantly reduced by simvastatin among participants with a history of cerebrovascular disease, there was a substantial reduction in the combined risk of all major vascular events (ie, heart attacks, strokes, and revascularisation procedures) among these patients.

Rory Collins comments: "This study shows that statin therapy rapidly reduces the incidence not only of heart attacks but also of ischaemic strokes, with no adverse effect on haemorrhagic strokes, even among individuals who do not have high cholesterol concentrations. Allocation to 40 mg simvast
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
4-Mar-2004


Page: 1 2

Related medicine news :

1. Statins effective in long term, Nordic study suggests
2. Statins show early promise for treating multiple sclerosis
3. Statins and aspirin may protect against severe vision loss in elderly
4. Statins may inhibit calcium growth on aortic valve in the elderly
5. International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports
6. Charcoal and forest management could reduce greenhouse gas levels & save lives in Africa
7. Novel therapy tested in mice could chase away cat allergies
8. Costs of antidepressants could have funded effective alternatives
9. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
10. Blood pressure treatment could cut risk of strokes and heart attacks
11. Proteins found in urine of pregnant women could help diagnose preeclampsia

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Statins could reduce stroke risk third

(Date:2/26/2015)... 2015 marks five years of being ... Caggiano! , Orthodontics is a perfect blend of ... background in biomedical engineering, his artistic talent, his extensive ... dentist allows Dr. Caggiano to create innovative approaches to ... named Orthodontic Products’ Best of 2012, a national recognition, ...
(Date:2/26/2015)... The hip resurfacing procedure at Texas Orthopedics has ... Short to resume his active lifestyle, it has improved his ... Kilimanjaro, the highest free-standing mountain in the world, in an ... late 20s, Short suffered from early onset degeneration. His condition ... bone on bone. , Then about five years ago, ...
(Date:2/26/2015)... CA (PRWEB) February 26, 2015 Beckman ... “Diversity of extracellular vesicles and their cargo in cell-to-cell ... vesicles and their relevance for cell-to-cell communication. The webinar ... March 4, 2015 at 8:00am PT. , Every cell ... extracellular vesicles (EVs) , often called “exosomes” or “microvesicles.” ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 2015 ... is a professional and in-depth study on the ... with a focus on the Chinese situation. ... are Lawton Gmbh & Co.KG, Hu-Friedy, Medisporex, Towne ... Instruments, Shuangyin, Shanghai Weirong Medical Equipment, Shuanglu, Changshu ...
(Date:2/26/2015)... 26, 2015 “ KnowNote ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... in rhythm and in tune. , Learning a musical instrument ... But what if people could take something they already know ...
Breaking Medicine News(10 mins):Health News:Dr. David Caggiano of Caggiano Orthodontics is Celebrating Five Years as an "NJ Top Dentist" ! 2Health News:Dr. David Caggiano of Caggiano Orthodontics is Celebrating Five Years as an "NJ Top Dentist" ! 3Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 2Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 3Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 2Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 3Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 2Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 3Health News:A Modern Way to Learn Music was Featured on NewsWatch Television on January 30, 2015 2
(Date:2/26/2015)... -- ABIVAX, a clinical stage biotech company developing ... it has dosed in New Zealand ... ABX203 which is taking place in several countries of the ... to assess whether ABX203 can deliver a significant improvement in ... load for a much longer period of time when compared ...
(Date:2/26/2015)... Medtronic, Inc. (U.S.), St. Jude Medical, ... in the Saudi Arabia , ... expected to lead the market during the period of 2014 ... player in the market, and owns a wide product portfolio ... Entera Neurostimulator are some of the most popular brands of ...
(Date:2/26/2015)... --  HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter ended December 31, 2014, a 38% ... same period of 2013.  For the fiscal year 2014, ... increase compared to revenue of $207.9 million in 2013.  ...
Breaking Medicine Technology:ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 2ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 3ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 4ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 5Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 2Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 3Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 4HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 2HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 3HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 4HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 5HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 6HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 7HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 8HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 9HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 10HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 11HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 12
Cached News: